References
- Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223–41
- Westermark P. Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci 2012;117:244–50
- Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009;30:93–103
- Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649–55
- Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200
- Glaudemans AW, Signore A. FDG-PET/CT in infections: the imaging method of choice? Eur J Nucl Med Mol Imaging 2010;37:1986–91
- Mekinian A, Jaccard A, Soussan M, Launay D, Berthier S, Federici L, Lefèvre G, et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid 2012;19:94–8
- Glaudemans AWJM, Slart RHJA, Noordzij W, Dierckx RAJO, Hazenberg BPC. Utility of 18F-FDG PET(/CT) in patients with systemic and local amyloidosis. Eur J Nucl Med Mol Imaging. In Press
- Gemmel F, Van den Wyngaert H, Love C, Welling MM, Gemmel P, Palestro CJ. Prosthetic joint infections: radionuclide state-of-the-art imaging. Eur J Nucl med Mol Imaging 2012;39:892–909